# Jean-François Pariseau

> Jean-François Pariseau is a Series A investor at Clementia Pharmaceuticals backing Medical. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Clementia Pharmaceuticals](https://shizune.co/investors/profile/clementia-pharmaceuticals)
- Location: Montréal, Canada
- Total investments: 12
- Last investment: Sep 2025
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/jeanfrancoispariseau
- X (Twitter): http://twitter.com/JFPariseau

Jean-François Pariseau is a Series A investor at Clementia Pharmaceuticals in Montréal focused on Medical and Health Care. Jean-François Pariseau is the Co-Founder and Partner of Amplitude Venture Capital & he attended Université de Montréal in 1992.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 4 | 33% |
| Health Care | 4 | 33% |
| Biotechnology | 4 | 33% |
| Biopharma | 2 | 17% |
| Medical Device | 2 | 17% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 42% |
| Funding Round | 4 | 33% |
| Seed | 1 | 8% |
| Convertible Note | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Canada | 6 | 50% |
| United States | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Thryv Therapeutics | Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventriculararrhythmias. Click below to learn more about our programs. |  |  | Sep 17, 2025 |  |
| Fluid Biomed | Fluid Biotech is a Calgary based company that aims to develop the next generation of stents to improve patient well-being and realise better health and quality of life through innovation. | $27M | Series A | Dec 16, 2024 |  |
| Thryv Therapeutics | Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventriculararrhythmias. Click below to learn more about our programs. | $19M | Series A | Aug 10, 2021 |  |
| Giiant Pharma | Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerabilityand enhanced therapeutic effect. | $12.4M | Seed | May 21, 2021 |  |
| Imagia | Imagia's mission is to leverage advances in artificial intelligence and accelerate the advent of accessible personalized medicine.The company's platform leverage advances in artificial intelligence to provide outcome-based structured clinical data and federated learning capabilities across multiple sources while preserving privacy,enabling clinicians to drive end-to-end discoveries of predictive, diagnostic, and prescriptive analytics. | $2.9M | Series A | Jan 01, 2018 |  |
| Clementia Pharmaceuticals | Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shownpotent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues.Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec. | $60M |  | Jun 23, 2015 |  |
| Profound Medical Inc | The Profound Medical team is committed to creating the powerful combination of real-time MR-guidance as the imaging platform and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patientsand clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives. | $20.1M |  | Apr 30, 2015 |  |
| Profound Medical Inc | The Profound Medical team is committed to creating the powerful combination of real-time MR-guidance as the imaging platform and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patientsand clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives. | $1.1M | Convertible Note | Jan 27, 2015 |  |
| Clementia Pharmaceuticals | Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shownpotent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues.Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec. | $10M | Series A | Jan 05, 2015 |  |
| Clementia Pharmaceuticals | Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shownpotent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues.Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec. | $22.5M | Series A | Jan 09, 2014 |  |

10 of 12 investments shown.

## Co-investors
- [Fonds de solidarité FTQ](https://shizune.co/investors/profile/fonds-de-solidarit-ftq) — VC Fund, 3 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 3 deals together
- [Amzak Health Investors](https://shizune.co/investors/profile/amzak-health-investors) — VC Fund, 2 deals together
- [Genesys Capital](https://shizune.co/investors/profile/genesys-capital) — VC Fund, 2 deals together
- [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures) — VC Fund, 2 deals together
- [adMare Bio Innovations](https://shizune.co/investors/profile/admare-bio-innovations) — VC Fund, 1 deal together

## About Clementia Pharmaceuticals

VC Fund · Montréal, Canada

Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shownpotent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues.Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec.

3 contacts available at Clementia Pharmaceuticals.

| Name | Title | Profile |
| --- | --- | --- |
| Clarissa Desjardins | CEO | https://shizune.co/investors/profile/clarissa-desjardins |
| Jean-François Pariseau | Board Member | https://shizune.co/investors/profile/jean-franois-pariseau |
| Michael Singer | Chief Financial Officer | https://shizune.co/investors/profile/michael-singer-7 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jean-François Pariseau invest in?

Jean-François Pariseau invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Funding Round stage. Most of the 12 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jean-François Pariseau last invest?

The most recent investment recorded for Jean-François Pariseau closed in Sep 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co